Biogen (BIIB) News Today $140.64 +3.56 (+2.60%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$140.62 -0.02 (-0.02%) As of 02/21/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period 2BIIB : Biogen Options Trading: A Deep Dive into Market SentimentFebruary 21 at 6:58 PM | benzinga.comBiogen Q4 Earnings TranscriptFebruary 21 at 7:22 AM | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Stock Position Increased by Meitav Investment House Ltd.Meitav Investment House Ltd. increased its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 510.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,838 shares of the biotechnologyFebruary 21 at 6:09 AM | marketbeat.comIeq Capital LLC Buys 55,514 Shares of Biogen Inc. (NASDAQ:BIIB)Ieq Capital LLC increased its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 1,380.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,534 shares of the biotechnology company's stock aftFebruary 21 at 4:44 AM | marketbeat.com3STOK, BIIB : Biogen Strengthens Pipeline With Stoke Therapeutic ...February 20 at 9:03 AM | benzinga.comBiogen Stock Is Mutating Into a Value PlayBiogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2XFebruary 20 at 7:42 AM | marketbeat.comICICI Prudential Asset Management Co Ltd Cuts Position in Biogen Inc. (NASDAQ:BIIB)ICICI Prudential Asset Management Co Ltd decreased its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 7.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,249 shares of the biFebruary 20 at 7:41 AM | marketbeat.comAlberta Investment Management Corp Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB)Alberta Investment Management Corp grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 138.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 33,180 shares of the biotechnology company's stock after purchasing an additional 19,280 shareFebruary 20 at 4:54 AM | marketbeat.comC2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $751,000 Position in Biogen Inc. (NASDAQ:BIIB)C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,913 shares of the biotechnologFebruary 20 at 4:28 AM | marketbeat.comBiogen (NASDAQ:BIIB) Earns "Neutral" Rating from Piper SandlerFebruary 20 at 2:34 AM | americanbankingnews.comAnalysts Set Biogen Inc. (NASDAQ:BIIB) Target Price at $211.96February 20 at 1:47 AM | americanbankingnews.comBiogen's (BIIB) "Neutral" Rating Reiterated at Piper SandlerPiper Sandler reiterated a "neutral" rating and set a $135.00 price objective (down from $138.00) on shares of Biogen in a research note on Tuesday.February 19 at 9:38 AM | marketbeat.comKentucky Retirement Systems Insurance Trust Fund Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB)Kentucky Retirement Systems Insurance Trust Fund lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 93.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,365 shares of the biotechnology company's sFebruary 19 at 5:39 AM | marketbeat.comEmpowered Funds LLC Reduces Stake in Biogen Inc. (NASDAQ:BIIB)Empowered Funds LLC lowered its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 77.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,277 shares of the biotechnology company's stockFebruary 19 at 3:13 AM | marketbeat.comBiogen, Stoke Therapeutics announce zorevunersen commercialization agreementFebruary 18, 2025 | markets.businessinsider.comBiogen price target lowered to $135 from $138 at Piper SandlerFebruary 18, 2025 | markets.businessinsider.comStoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsyFebruary 18, 2025 | marketwatch.comBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsFebruary 18, 2025 | globenewswire.comRhumbline Advisers Has $41.07 Million Stock Position in Biogen Inc. (NASDAQ:BIIB)Rhumbline Advisers lessened its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 2.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 268,591 shares of the biotechnology company's stock after selling 5,718 shares during the quarter. RhumblineFebruary 18, 2025 | marketbeat.comAsset Management One Co. Ltd. Buys 2,871 Shares of Biogen Inc. (NASDAQ:BIIB)Asset Management One Co. Ltd. boosted its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 5.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 58,226 shares of the biotechnology company's stock after buying an additional 2,871 shFebruary 18, 2025 | marketbeat.comWilliam Blair Brokers Boost Earnings Estimates for BiogenFebruary 18, 2025 | americanbankingnews.comWedbush Brokers Reduce Earnings Estimates for BiogenFebruary 18, 2025 | americanbankingnews.com19,574 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Strategic Financial Concepts LLCStrategic Financial Concepts LLC purchased a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 19,574 shares of the biotechnology company's stoFebruary 17, 2025 | marketbeat.comNew York State Teachers Retirement System Sells 6,673 Shares of Biogen Inc. (NASDAQ:BIIB)New York State Teachers Retirement System lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 5.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 111,128 shares of the biotechnology company's stock after selling 6,673 shares duriFebruary 17, 2025 | marketbeat.comVontobel Holding Ltd. Increases Position in Biogen Inc. (NASDAQ:BIIB)Vontobel Holding Ltd. increased its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 36.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,262 shares of the biotechnology company's stock afterFebruary 17, 2025 | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Given Average Recommendation of "Hold" by BrokeragesBiogen Inc. (NASDAQ:BIIB - Get Free Report) has earned an average recommendation of "Hold" from the thirty research firms that are currently covering the stock, Marketbeat Ratings reports. Seventeen research analysts have rated the stock with a hold rating and thirteen have given a buy rating to tFebruary 17, 2025 | marketbeat.comResearch Analysts Offer Predictions for Biogen Q2 EarningsBiogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at William Blair lifted their Q2 2025 EPS estimates for Biogen in a note issued to investors on Wednesday, February 12th. William Blair analyst M. Minter now forecasts that the biotechnology company will earn $4.20 per share for the quarterFebruary 17, 2025 | marketbeat.comWedbush Has Pessimistic Outlook of Biogen Q1 EarningsBiogen Inc. (NASDAQ:BIIB - Free Report) - Equities research analysts at Wedbush lowered their Q1 2025 EPS estimates for shares of Biogen in a research report issued to clients and investors on Thursday, February 13th. Wedbush analyst L. Chico now expects that the biotechnology company will post eFebruary 17, 2025 | marketbeat.comWilliam Blair Issues Optimistic Estimate for Biogen EarningsFebruary 16, 2025 | americanbankingnews.comQ1 Earnings Estimate for Biogen Issued By Leerink PartnrsFebruary 16, 2025 | americanbankingnews.comBiogen (NASDAQ:BIIB) Given New $225.00 Price Target at Royal Bank of CanadaFebruary 16, 2025 | americanbankingnews.comNeedham & Company LLC Reaffirms Hold Rating for Biogen (NASDAQ:BIIB)February 16, 2025 | americanbankingnews.comScotiabank Cuts Biogen (NASDAQ:BIIB) Price Target to $224.00February 16, 2025 | americanbankingnews.comBiogen (NASDAQ:BIIB) Given New $265.00 Price Target at Canaccord Genuity GroupFebruary 16, 2025 | americanbankingnews.comFY2025 EPS Estimates for Biogen Cut by Cantor FitzgeraldFebruary 16, 2025 | americanbankingnews.comBiogen (NASDAQ:BIIB) Price Target Cut to $139.00 by Analysts at BMO Capital MarketsFebruary 16, 2025 | americanbankingnews.comThe Goldman Sachs Group Issues Pessimistic Forecast for Biogen (NASDAQ:BIIB) Stock PriceFebruary 16, 2025 | americanbankingnews.comCantor Fitzgerald Brokers Cut Earnings Estimates for BiogenBiogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for Biogen in a research report issued on Thursday, February 13th. Cantor Fitzgerald analyst E. Schmidt now expects that the biotechnology company will earn $16.13 per share for the yeFebruary 15, 2025 | marketbeat.comQ1 Earnings Forecast for Biogen Issued By Leerink PartnrsBiogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Biogen in a research note issued to investors on Wednesday, February 12th. Leerink Partnrs analyst M. Goodman anticipates that the biotechnology company will earn $3.84 perFebruary 15, 2025 | marketbeat.comWilliam Blair Issues Positive Outlook for Biogen EarningsBiogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at William Blair raised their Q1 2025 earnings estimates for shares of Biogen in a note issued to investors on Wednesday, February 12th. William Blair analyst M. Minter now anticipates that the biotechnology company will post earnings per sFebruary 15, 2025 | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Shares Purchased by Banque Pictet & Cie SABanque Pictet & Cie SA boosted its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 106.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,494 shares of the biotechnology company's stock after buFebruary 15, 2025 | marketbeat.comBiogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' PharmaFebruary 15, 2025 | seekingalpha.comStephens Inc. AR Has $481,000 Stock Holdings in Biogen Inc. (NASDAQ:BIIB)Stephens Inc. AR cut its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 41.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,145 shares of the biotechnology company's stock after selling 2,270 sharesFebruary 15, 2025 | marketbeat.comC2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes Position in Biogen Inc. (NASDAQ:BIIB)C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 4,913 shares of the biotFebruary 14, 2025 | marketbeat.comBiogen (NASDAQ:BIIB) Trading Down 6.8% After Analyst DowngradeFebruary 14, 2025 | americanbankingnews.comBiogen price target lowered to $139 from $156 at BMO CapitalFebruary 13, 2025 | markets.businessinsider.comLeqembi And Skyclarys Expected To Drive Biogen's Future Growth: AnalystsFebruary 13, 2025 | benzinga.comLeqembi And Skyclarys Expected To Drive Biogen's Future Growth: AnalystsFebruary 13, 2025 | benzinga.comBiogen (NASDAQ:BIIB) Price Target Lowered to $224.00 at ScotiabankScotiabank lowered their price target on shares of Biogen from $244.00 to $224.00 and set a "sector outperform" rating on the stock in a report on Thursday.February 13, 2025 | marketbeat.comBiogen (NASDAQ:BIIB) Price Target Lowered to $139.00 at BMO Capital MarketsBMO Capital Markets reduced their target price on Biogen from $156.00 to $139.00 and set a "market perform" rating for the company in a report on Thursday.February 13, 2025 | marketbeat.com Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address BIIB Media Mentions By Week BIIB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIIB News Sentiment▼0.570.60▲Average Medical News Sentiment BIIB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIIB Articles This Week▼5622▲BIIB Articles Average Week Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Regeneron Pharmaceuticals News Today Alnylam Pharmaceuticals News Today United Therapeutics News Today Incyte News Today BioMarin Pharmaceutical News Today Neurocrine Biosciences News Today Exelixis News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIIB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BIIB with Qtrade Free BIIB Stock Alerts